277 related articles for article (PubMed ID: 15698860)
1. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
[TBL] [Abstract][Full Text] [Related]
2. Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.
Baldew GS; McVie JG; van der Valk MA; Los G; de Goeij JJ; Vermeulen NP
Cancer Res; 1990 Nov; 50(21):7031-6. PubMed ID: 2208170
[TBL] [Abstract][Full Text] [Related]
3. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
Lee CK; Park KK; Hwang JK; Lee SK; Chung WY
Phytother Res; 2009 Jul; 23(7):999-1005. PubMed ID: 19140122
[TBL] [Abstract][Full Text] [Related]
4. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
5. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
[TBL] [Abstract][Full Text] [Related]
6. Thea sinensis melanin prevents cisplatin-induced nephrotoxicity in mice.
Hung YC; Huang GS; Lin LW; Hong MY; Se PS
Food Chem Toxicol; 2007 Jul; 45(7):1123-30. PubMed ID: 17303299
[TBL] [Abstract][Full Text] [Related]
7. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
8. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase.
Zhang J; Wang X; Lu H
Cancer Lett; 2008 Feb; 260(1-2):127-36. PubMed ID: 18039557
[TBL] [Abstract][Full Text] [Related]
9. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
[TBL] [Abstract][Full Text] [Related]
10. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues.
Aleisa AM; Al-Majed AA; Al-Yahya AA; Al-Rejaie SS; Bakheet SA; Al-Shabanah OA; Sayed-Ahmed MM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1252-9. PubMed ID: 17973863
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway.
Wainford RD; Weaver RJ; Stewart KN; Brown P; Hawksworth GM
Toxicology; 2008 Jul; 249(2-3):184-93. PubMed ID: 18583013
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cisplatin-induced nephrotoxicity by glucosides of ascorbic acid and alpha-tocopherol.
Maliakel DM; Kagiya TV; Nair CK
Exp Toxicol Pathol; 2008 Sep; 60(6):521-7. PubMed ID: 18644706
[TBL] [Abstract][Full Text] [Related]
13. Direct amifostine effect on renal tubule cells in rats.
Weichert-Jacobsen KJ; Bannowski A; Küppers F; Loch T; Stöckle M
Cancer Res; 1999 Jul; 59(14):3451-3. PubMed ID: 10416609
[TBL] [Abstract][Full Text] [Related]
14. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
Kim WK; Kwon YE
Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
[TBL] [Abstract][Full Text] [Related]
15. Tannic acid mitigates cisplatin-induced nephrotoxicity in mice.
Ahmad ST; Sultana S
Hum Exp Toxicol; 2012 Feb; 31(2):145-56. PubMed ID: 21724663
[TBL] [Abstract][Full Text] [Related]
16. Xanthorrhizol has a potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice.
Kim SH; Hong KO; Hwang JK; Park KK
Food Chem Toxicol; 2005 Jan; 43(1):117-22. PubMed ID: 15582203
[TBL] [Abstract][Full Text] [Related]
17. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
18. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
[TBL] [Abstract][Full Text] [Related]
19. Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice.
Nakashima-Kamimura N; Mori T; Ohsawa I; Asoh S; Ohta S
Cancer Chemother Pharmacol; 2009 Sep; 64(4):753-61. PubMed ID: 19148645
[TBL] [Abstract][Full Text] [Related]
20. Licochalcone A inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice.
Lee CK; Son SH; Park KK; Park JH; Lim SS; Kim SH; Chung WY
Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):48-54. PubMed ID: 18484961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
